NCT05535673View on ClinicalTrials.gov

Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma

PHASE1UnknownINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 2, 2022

Primary Completion Date

July 1, 2025

Study Completion Date

July 1, 2025

Conditions

Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited, r/r B-NHL

Interventions

DRUG

ThisCART19A

In this study, allogeneic anti-CD19 CAR-T cell (ThisCART19A) injection is used to treat patients with refractory or relapsed CD19 positive B cell Lymphoma.